Warren Buffett’s company Berkshire Hathaway sold off millions of dollars in shares from airline companies Delta Air Lines and Southwest Airlines, after the coronavirus pandemic slammed the airline industry. Yahoo Finance’s On The Move panel breaks down the latest....
Richard Bishop, AI industry analyst and intelligent vehicle applications specialist, spoke with Jim Park about autonomous trucks for an episode of the HDT Talks Trucking podcast. ...
Stocks extended gains Monday as investors braced for another week of closely monitoring developments around the global coronavirus outbreak and policymakers’ responses to the pandemic....
Stocks extended gains Monday as investors braced for another week of closely monitoring developments around the global coronavirus outbreak and policymakers’ responses to the pandemic....
British drugmaker GlaxoSmithKline (GSK) and Vir Biotechnology Inc (VIR) on Monday announced a partnership to develop potential antibody treatments for COVID-19, the disease caused by the coronavirus.As part of the collaboration agreement GSK will make an investment in Vir of $250 million, priced at $37.73, representing a 10% premium to the closing share price on March 27, 2020, according to the announcement. Vir’s shares soared as much as 34% rising to around $39 in early U.S. trading following the news of GSK’s investment.Wall Street analysts take a cautious stance on Vir’s stock. The Hold analyst consensus rating is based on 2 Sells, 2 Buys and 1 Hold. The $31 average price target projects 16% downside potential in the shares in the next 12 months. (See Vir’s stock analysis on TipRanks) In the initial phase of the collaboration, the target will be to accelerate the development of specific antibody candidates identified by Vir’s...
